Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorHurley, James C.en_US
dc.description.abstractBackground: Topical polymyxin (PM), in various applications, has been studied as a method for VAP prevention. The effect of topical PM toward preventing Acinetobacter associated VAP (AAVAP) is unknown. The objectives here are to estimate this effect size within randomized controlled trials (RCT’s) and also to reconcile the incidence of AAVAP within the control and intervention groups of these same RCT’s versus an external benchmarked. Material/methods: A meta-analysis and meta-regression using generalized estimating equation (GEE) methods of AAVAP incidence among patients receiving prolonged mechanical ventilation as reported in RCT’s of topical PM based interventions. AAVAP data from 42 studies of a range of interventions other than topical PM (non PM studies) served as additional points of reference. AAVAP benchmarks were derived from 71 observational groups [Ob] without any VAP prevention method under study. Results: The effect size within RCT’s of topical PM on AAVAP is 0.61 (95% confidence interval, CI; 0.4-0.93; n=15). Surprisingly, the mean AAVAP is 4.9% (95% CI 3.0 – 6.8) and 3.7% (95% CI 1.9 - 5.4) for control groups [C] and intervention groups [I] of 20 topical PM studies, respectively, versus 2.7% (95% CI; 2.1-3.4) for the AAVAP benchmark [figure]. In the meta-regression models, membership of the following are significantly correlated with each of VAP and AAVAP; a trauma ICU (positively) and a North American ICU (negatively), whereas for the AAVAP model membership of a topical PM intervention group was not significantly correlated. Conclusions: An unidentified contextual factor confounds the apparent preventative effect of topical PM based interventions with a result that AAVAP incidences within these studies are higher than expected. Other observations implicate cross infection as the basis for this unidentified contextual factor.en_US
dc.description.provenanceSubmitted by Gemma Siemensma ( on 2018-04-26T04:06:12Z No. of bitstreams: 1 jhurley_ESCMID_2017.pdf: 451552 bytes, checksum: 12a7298e6bbb4d3d0e0cb4235d2b7a30 (MD5)en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma ( on 2018-05-04T06:18:29Z (GMT) No. of bitstreams: 1 jhurley_ESCMID_2017.pdf: 451552 bytes, checksum: 12a7298e6bbb4d3d0e0cb4235d2b7a30 (MD5)en
dc.description.provenanceMade available in DSpace on 2018-05-04T06:18:29Z (GMT). No. of bitstreams: 1 jhurley_ESCMID_2017.pdf: 451552 bytes, checksum: 12a7298e6bbb4d3d0e0cb4235d2b7a30 (MD5) Previous issue date: 2017en
dc.titlePolymyxin applied to the respiratory tract fails to prevent Acinetobacter-associated ventilator-associated pneumonia: benchmarking the evidence base.en_US
dc.bibliographicCitation.conferencedateApril 22-25, 2017en_US
dc.bibliographicCitation.conferencenameECCMID 2018: The 27th European Congress of Clinical Microbiology and Infectious Diseasesen_US
dc.bibliographicCitation.conferenceplaceVienna, Austriaen_US
dc.subject.healththesaurusVENTILATOR ASSOCIATED PNEUMONIAen_US
dc.subject.healththesaurusCROSS INFECTIONen_US
dc.subject.healththesaurusRESPIRATION, ARTIFICIALen_US
dc.subject.healththesaurusCONTROL GROUPSen_US
Appears in Collections:Research Output

Files in This Item:
File Description SizeFormat  
jhurley_ESCMID_2017.pdf440.97 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.